224 related articles for article (PubMed ID: 19691369)
1. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Br J Cancer; 2008 Mar; 98(5):900-6. PubMed ID: 18319714
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A
Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.
Kloft C; Graefe EU; Tanswell P; Scott AM; Hofheinz R; Amelsberg A; Karlsson MO
Invest New Drugs; 2004 Jan; 22(1):39-52. PubMed ID: 14707493
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
12. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
[TBL] [Abstract][Full Text] [Related]
13. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
Lu JF; Bruno R; Eppler S; Novotny W; Lum B; Gaudreault J
Cancer Chemother Pharmacol; 2008 Oct; 62(5):779-86. PubMed ID: 18205003
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors.
Ma P; Yang BB; Wang YM; Peterson M; Narayanan A; Sutjandra L; Rodriguez R; Chow A
J Clin Pharmacol; 2009 Oct; 49(10):1142-56. PubMed ID: 19723673
[TBL] [Abstract][Full Text] [Related]
18. Target-mediated drug disposition model for drugs that bind to more than one target.
Gibiansky L; Gibiansky E
J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
Sharma S; Mittapalli RK; Holen KD; Xiong H
Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Samtani MN; Vermeulen A; Stuyckens K
Clin Pharmacokinet; 2009; 48(9):585-600. PubMed ID: 19725593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
